This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
zacks-consensus-estimate: Archive
Lands' End (LE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lands' End (LE) delivered earnings and revenue surprises of -100.00% and -8.78%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
LEPositive Net Change KMXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Oracle (ORCL) Meets Q1 Earnings Estimates
by Zacks Equity Research
Oracle (ORCL) delivered earnings and revenue surprises of 0.00% and -0.59%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
ORCLNegative Net Change ADBEPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Lakeland Industries (LAKE) Q2 Earnings Top Estimates
by Zacks Equity Research
Lakeland Industries (LAKE) delivered earnings and revenue surprises of +1,000.00% and -1.51%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
LAKEPositive Net Change APOGPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Matrix Service (MTRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Matrix Service (MTRX) delivered earnings and revenue surprises of -1,500.00% and -7.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MTRXNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Synopsys (SNPS) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Synopsys (SNPS) delivered earnings and revenue surprises of -11.72% and -1.61%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
SNPSPositive Net Change PRGSPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
GameStop (GME) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
GameStop (GME) delivered earnings and revenue surprises of +31.58% and +8.02%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
GMEPositive Net Change HOFTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Will Zumiez (ZUMZ) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Zumiez (ZUMZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
ZUMZPositive Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Earnings Estimates Rising for Credo Technology Group (CRDO): Will It Gain?
by Zacks Equity Research
Credo Technology Group Holding Ltd. (CRDO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CRDONegative Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
All You Need to Know About WSFS (WSFS) Rating Upgrade to Buy
by Zacks Equity Research
WSFS (WSFS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WSFSNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
REV Group (REVG) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
REV Group (REVG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
REVGNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
IZEA WORLDWIDE (IZEA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
IZEA WORLDWIDE (IZEA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IZEAPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Bank OZK (OZK) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Bank OZK (OZK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OZKPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Swire Pacific (SWRAY) Rating Upgrade to Buy
by Zacks Equity Research
Swire Pacific (SWRAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SWRAYNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ELVNPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Compass Group (CMPGY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Compass Group (CMPGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CMPGYPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Farmer Mac (AGM) a New Buy Stock
by Zacks Equity Research
Farmer Mac (AGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AGMNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
by Zacks Equity Research
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MCRBPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
SouthState (SSB) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
SouthState (SSB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SSBPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 294.8% upside potential for Astria Therapeutics (ATXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ATXSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can Carpenter (CRS) Climb 26.25% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 26.3% upside potential for Carpenter (CRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CRSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Sionna Therapeutics, Inc. (SION) points to a 66.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SIONPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SDGRPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Sezzle Inc. (SEZL) Could Rally 49.63%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 49.6% in Sezzle Inc. (SEZL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SEZLNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Earnings Growth & Price Strength Make CBRE Group (CBRE) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
CBREPositive Net Change
earnings-estimates growth-investing zacks-consensus-estimate zacks-rank
Why Lam Research (LRCX) is a Top Stock for the Long-Term
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
LRCXPositive Net Change
earnings-estimates growth-investing zacks-consensus-estimate zacks-rank